Vinorelbine

Drug Profile

Vinorelbine

Alternative Names: KW-2307; Navelbine; NVB; Vinorelbine ditartrate; Vinorelbine tartrate

Latest Information Update: 20 Jul 2017

Price : $50

At a glance

  • Originator CNRS
  • Developer Amgen; Bristol-Myers Squibb; Pierre Fabre; University of Washington
  • Class Antineoplastics; Small molecules; Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Non-small cell lung cancer
  • Phase II Mesothelioma
  • No development reported Cervical cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Small cell lung cancer
  • Discontinued Multiple myeloma

Most Recent Events

  • 08 Jul 2017 Pierre Fabre Pharma suspends patient enrolment in the phase II VinoMetro trial for Breast cancer (Metastatic disease, First-line therapy, Late-stage disease) in Germany (PO) (NCT03007992)
  • 08 May 2017 GlaxoSmithKline terminates a phase I/II trial as the sponsor withdrew the study in Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT00041470)
  • 07 Oct 2016 Final safety and efficacy results from the phase II NAVoTRIAL presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top